Ekso Bionics® to Showcase New Industrial Construction Solution for Heavy Tool Handling at World of Concrete
January 11 2017 - 05:18PM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced it will showcase its innovative EksoZeroG
technology at the World of Concrete (WOC 2017) event January 17-20,
2017, in Las Vegas. The EksoZeroG, a lightweight assistive device
for industrial workers, provides an exciting new solution to
enhance productivity and workmanship as well as to reduce
work-related injuries on construction sites.
“EksoZeroG is the first product in an industrial
line that is a strategic priority for Ekso Bionics. The
industrial product portfolio seeks to leverage our broad
intellectual property, engineering expertise and extensive field
testing with key industrial partners,“ said Tom Looby Chief
Executive Officer.
Ekso Works, the industrial division of Ekso
Bionics, produces the EksoZeroG, which is a versatile, lightweight
device that easily mounts to aerial work platform rails or
scaffolding and has multiple tool holders to accommodate a wide
range of tools. The technology, which is designed to hold heavy
tools and thereby offset the direct load from the tool operator,
flexes effortlessly, easily following directional guidance during
work.
“We are committed to developing innovative
technology that makes it easier and safer for skilled workers to
continue doing their jobs on construction worksites,” said Russ
Angold, Co-Founder and Chief Technology Officer, Ekso Bionics.
“EksoZeroG technology has been specifically designed to amplify
workers by bearing the weight of heavy construction tools, such as
rotary hammers and pneumatic chipping guns, during operation. This
assistive technology reduces fatigue and injury risk for workers
and can increase productivity during these heavy duty applications.
Our ultimate goal is to keep workers healthy, happy and
productive.”
The Ekso Bionics industrial product line seeks to
address one of the biggest challenges facing the construction
industry today – protecting workers while finishing jobs on time
and within budget. Many companies are seeing a trend of
increasing costs related to worker safety, driven primarily by
worker fatigue, strain and other job-related injuries. With Ekso
Bionics’ innovative technology, workers can complete heavy tool
tasks with less fatigue, better workmanship and fewer workplace
injuries.
At the Ekso Bionics outdoor booth, #O30608,
visitors are invited to try the EksoZeroG and experience for
themselves how this innovative technology can significantly help
workers in this field.
To learn more about EksoZeroG, visit
www.eksobionics.com and connect with us on LinkedIn, Facebook,
Twitter, and YouTube.
About World of ConcreteWorld of
Concrete is the industry’s only annual international event
dedicated to the commercial concrete and masonry construction
industries showcasing leading industry suppliers featuring
innovative products, construction machinery, construction
equipment, safety training courses, new technologies and unlimited
networking opportunities to give you new ways to sustain and grow
your business.
About Ekso Bionics® Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable exoskeletons available on the market. Ekso
Bionics is the only exoskeleton company to offer technologies that
range from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe, to
providing research for the advancement of R&D projects intended
to benefit U.S. defense capabilities. The company is headquartered
in the Bay Area and is listed on the Nasdaq Capital Market under
the symbol EKSO. For more information,
visit: www.eksobionics.com.
Forward-Looking Statements Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) a projection of financial results, financial condition,
capital expenditures, capital structure or other financial items,
(iii) the Company's future financial performance and (iv) the
assumptions underlying or relating to any statement described in
points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are
based upon the Company's current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to
a number of risks and uncertainties and other influences, many of
which the Company has no control over. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing to fund the Company's operations and
necessary to develop or enhance our technology, the significant
length of time and resources associated with the development of the
Company's products, the Company's failure to achieve broad market
acceptance of the Company's products, the failure of our sales and
marketing organization or partners to market our products
effectively, adverse results in future clinical studies of the
Company's medical device products, the failure to obtain or
maintain patent protection for the Company's technology, failure to
obtain or maintain regulatory approval to market the Company's
medical devices, lack of product diversification, existing or
increased competition, and the Company's failure to implement the
Company's business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Glenn Silver
646-871-8485
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2023 to Mar 2024